Stockscreener 앱 받기
66.75
2.18%
-1.49
시간 외 거래:
66.75
전일 마감가:
$68.24
열려 있는:
$67.77
하루 거래량:
461.60K
Relative Volume:
0.76
시가총액:
$2.84B
수익:
$451.36M
순이익/손실:
$-66.42M
주가수익비율:
-41.47
EPS:
-1.6097
순현금흐름:
$-22.31M
1주 성능:
-2.08%
1개월 성능:
+1.85%
6개월 성능:
+21.36%
1년 성능:
+34.71%
1일 변동 폭
$66.23
$67.77
1주일 범위
$66.23
$70.35
52주 변동 폭
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
66.75 | 2.90B | 451.36M | -66.42M | -22.31M | -1.6097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-11-20 | 개시 | Mizuho | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
TARS (NASDAQ: TARS) files notice to sell 2,186 shares via Fidelity - Stock Titan
TARS (NASDAQ: TARS) insider notifies sale of 4,440 shares via Fidelity - Stock Titan
TARS (NASDAQ: TARS) insider filings show proposed sale and recent dispositions - Stock Titan
Dianne Whitfield reports planned stock sales — TARS (NASDAQ: TARS) - Stock Titan
TARS (NASDAQ: TARS) insider files Form 144 to resell 4,589 shares after vesting - Stock Titan
TARS (NASDAQ: TARS) insider files Rule 144 to offer 390 shares after vesting - Stock Titan
Q1 Earnings Estimate for TARS Issued By Lifesci Capital - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Sell Alert: LINK WILLIAM J PHD Sells 12,500 Shares of Ta - GuruFocus
Tarsus Pharmaceuticals director Link sells $859k in stock By Investing.com - Investing.com India
Tarsus Pharmaceuticals director Link sells $859k in stock - Investing.com
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - MSN
William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Dianne Whitfield notifies sale of 4,071 TARS shares (NASDAQ: TARS) - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $859,819, According to a Recent SEC Filing - marketscreener.com
Insider sale notice: Bryan Wahl to sell 4,125 shares (TARS) - Stock Titan
Bobak Azamian (TARS) files Rule 144 to sell 11,667 vested shares - Stock Titan
TARS (NASDAQ: TARS) reports insider sales and a 3,610-share vesting on Form 144 - Stock Titan
Aziz A. Mottiwala to sell 4,330 shares (NASDAQ: TARS) on 03/17/2026 - Stock Titan
Insider sale after RSU vesting — TARS (NASDAQ: TARS) files Form 144 - Stock Titan
Tarsus (TARS) director William J. Link sells 12,500 shares in planned trades - Stock Titan
Tarsus Pharmaceuticals, Inc. (TARS) reports Q4 loss, beats revenue estimates - MSN
Tarsus Pharmaceuticals (NASDAQ:TARS) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
Tarsus (TARS) HR chief settles RSUs, holds 47,302 common shares - Stock Titan
Tarsus Pharmaceuticals (NASDAQ: TARS) general counsel exercises 24,236 RSUs - Stock Titan
Tarsus (NASDAQ: TARS) CCO receives 26,482 shares from RSUs - Stock Titan
Jeffrey Farrow of Tarsus (TARS) acquires 13,042 shares through RSU settlement - Stock Titan
Tarsus (TARS) CEO adds 66,274 shares via RSU settlement - Stock Titan
Tarsus (NASDAQ: TARS) CMO gains 2,511 shares in RSU settlement - Stock Titan
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
TARS (NASDAQ: TARS) insider files to sell 4,029 shares after vesting - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
TARS PE Ratio & Valuation, Is TARS Overvalued - Intellectia AI
TARS (NASDAQ: TARS) affiliate notifies sale of 2,133 vested shares - Stock Titan
Tarsus Pharmaceuticals (TARS) files Section 144 notice to sell 12,500 shares - Stock Titan
Sentiment Recap: Why is Tarsus Pharmaceuticals Inc stock going downShort Setup & Stock Portfolio Risk Management - baoquankhu1.vn
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Capitolis Liquid Global Markets LLC - MarketBeat
Ally Bridge Group NY LLC Decreases Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
COO at Tarsus (NASDAQ: TARS) gets 26,287 common shares from RSUs - Stock Titan
Integral Health Asset Management LLC Has $14.86 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 6.1%Should You Sell? - MarketBeat
Quantbot Technologies LP Reduces Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
(TARS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Jefferies Financial Group Inc. - MarketBeat
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First 2026 XDEMVY Sales Outlook - Sahm
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth - TipRanks
Stock option and RSU grants for Tarsus (NASDAQ: TARS) executive - Stock Titan
Tarsus (TARS) Chief Commercial Officer receives new option and RSU grants - Stock Titan
Tarsus (TARS) COO receives new stock option and RSU equity grants - Stock Titan
Tarsus (TARS) CHRO granted 27,310 options and 17,161 RSUs - Stock Titan
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):